摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-phenoxybutan-1-ol | 1927-71-5

中文名称
——
中文别名
——
英文名称
4-phenoxybutan-1-ol
英文别名
4-phenoxybutanol;4-Phenoxy-1-butanol
4-phenoxybutan-1-ol化学式
CAS
1927-71-5
化学式
C10H14O2
mdl
MFCD00518629
分子量
166.22
InChiKey
OYQUCYCSSADEIC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    36 °C
  • 沸点:
    162-164 °C(Press: 12 Torr)
  • 密度:
    1.0334 g/cm3

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    12
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2909499000

SDS

SDS:b0273980eab2d5d071007aecef8e7a67
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    (4-碘丁氧基)苯 4-phenoxybutyl iodide 20549-72-8 C10H13IO 276.117
    4-苯氧基丁基溴 4-bromophenyl butyl ether 1200-03-9 C10H13BrO 229.117
    4-苯氧基丁酸 4-phenyloxybutanoic acid 6303-58-8 C10H12O3 180.203
    4-苯氧基丁酸乙酯 ethyl 4-phenoxybutanoate 2364-59-2 C12H16O3 208.257
    烯丙基苯基醚 allyl phenyl ether 1746-13-0 C9H10O 134.178
    —— 4-phenoxybut-2-yn-1-ol 32833-70-8 C10H10O2 162.188
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    —— (4-methoxybutoxy)benzene 20636-14-0 C11H16O2 180.247
    (4-碘丁氧基)苯 4-phenoxybutyl iodide 20549-72-8 C10H13IO 276.117
    4-苯氧基丁基溴 4-bromophenyl butyl ether 1200-03-9 C10H13BrO 229.117
    —— (4-fluorobutoxy)benzene 70659-95-9 C10H13FO 168.211
    —— 5-phenoxypentan-1-ol 16654-52-7 C11H16O2 180.247
    4-氯丁基苯基醚 (4-chlorobutoxy)benzene 2651-46-9 C10H13ClO 184.666
    5-苯氧基正戊酸 5-phenoxyvaleric acid 7170-40-3 C11H14O3 194.23
    —— [4-[(6-bromohexyl)oxy]butoxy]benzene 119967-18-9 C16H25BrO2 329.277
    —— 4-Phenoxy-butyl-trimethylsilylaether 16654-51-6 C13H22O2Si 238.402
    三甲基[(5-苯氧基戊基)氧基]硅烷 5-Phenoxy-pentyl-trimethylsilylaether 16654-53-8 C14H24O2Si 252.429
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    4-phenoxybutan-1-ol氧气copper(l) chloride 作用下, 以 二甲基亚砜 为溶剂, 120.0 ℃ 、101.33 kPa 条件下, 反应 6.0h, 以55%的产率得到对苯醌
    参考文献:
    名称:
    通过连续的C–C键裂解 将羟基化合物逐步降解为醛†
    摘要:
    通过使用不带任何配体和添加剂的双金属催化体系(PdCl 2 + CuCl),通过C-C键的连续裂解将羟基化合物逐步降解为醛。广泛的适用性扩展到芳族,脂肪族,伯和仲醇以及木质素模型化合物的各种范围。
    DOI:
    10.1039/c8cc09504c
  • 作为产物:
    描述:
    4-苯氧基丁基溴偶氮二异丁腈三正丁基氢锡 、 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 12.0h, 生成 4-phenoxybutan-1-ol
    参考文献:
    名称:
    Facile Generation of Alkoxy Radicals from N-Alkoxyphthalimides
    摘要:
    N-烷氧基邻苯二甲酰亚胺,从醇和卤代烷中稳定且易于获得,被发现是非常高效的烷氧基自由基前体。
    DOI:
    10.1055/s-1998-1711
点击查看最新优质反应信息

文献信息

  • Sulfamates as antiglaucoma agents
    申请人:A. H. Robins Company, Incorporated
    公开号:US05192785A1
    公开(公告)日:1993-03-09
    Sulfamate esters of the formula (HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z where A is aryloxyalkyl, p is the number of unreacted hydroxy groups present on the alkyl moiety and may be zero, z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups attached to carbons of the alkyl moiety and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy, and the like are useful in treating glaucoma.
    Sulfamate酯的化学式为(HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z,其中A为芳基氧烷基,p为烷基部分上存在的未反应羟基的数量,可以为零,z为连接到烷基部分碳上的--OS(O).sub.2 NR.sup.1 R.sup.2基团的数量,始终至少为一;R.sup.1和R.sup.2从氢、低烷基、羧基等中选择,在治疗青光眼方面是有用的。
  • Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
    申请人:A. H. Robins Co., Inc.
    公开号:US05025031A1
    公开(公告)日:1991-06-18
    Herein disclosed is a method of treating convulsions with a pharmaceutical composition containing a compound of the formula: (HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z where A is an aryl, arylalkyl, or aryloxyalkyl group and is substituted on 1 or more carbon atoms with a sulfamate group (--OSO.sub.2 NR.sup.1 R.sup.2) wherein R.sup.1 and R.sup.2, same or different, are hydrogen or loweralkyl wherein p is 0 or 1 and is the number of untreated hydroxyl groups and z is 1 or 2 and is the number of --OS(O.sub.2)NR.sup.1 R.sup.2 groups. Aryl is selected from phenyl, substituted phenyl, pyridinyl, naphthyl, quinolinyl, and the like. Phenyl substituents are selected from hydrogen, halo, hydroxy, phenyl, phenoxy, benzoyl, loweralkyl, loweralkoxy, carboxy, amino, loweralkylamino, diloweralkylamino, acetamido, cyano, nitro, loweralkoxycarboyl, aminosulfonyl, imidazolyl, triazolyl, and the like. Novel compounds not previously disclosed are also described.
    以下披露了一种使用含有化合物的药物组合物来治疗惊厥的方法:(HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z,其中A是芳基、芳基烷基或芳氧烷基基团,并在1个或多个碳原子上用磺酰胺基团(--OSO.sub.2 NR.sup.1 R.sup.2)取代,其中R.sup.1和R.sup.2,相同或不同,是氢或较低烷基,其中p为0或1,是未处理的羟基团的数量,z为1或2,是--OS(O.sub.2)NR.sup.1 R.sup.2基团的数量。芳基选自苯基、取代苯基、吡啶基、萘基、喹啉基等。苯基取代基选自氢、卤素、羟基、苯基、苯氧基、苯甲酰基、较低烷基、较低烷氧基、羧基、氨基、较低烷基氨基、二较低烷基氨基、乙酰胺基、氰基、硝基、较低烷氧羰基、氨基磺酰基、咪唑基、三唑基等。还描述了以前未披露的新化合物。
  • [EN] (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS<br/>[FR] DÉRIVÉS DE (THIO)MORPHOLINE MODULATEURS DE S1P
    申请人:ABBOTT HEALTHCARE PRODUCTS BV
    公开号:WO2011023795A1
    公开(公告)日:2011-03-03
    The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.
    本发明涉及公式(I)的(硫)吗啉衍生物,其中R1从氰基,(2-4C)炔基,(1-4C)烷基,(3-6C)环烷基,(4-6C)环烯基,(6-8C)双环烷基,(8-10C)双环基团中选择,每个基团可选择地取代为(1-4C)烷基,苯基,联苯基,萘基,每个基团可选择地取代为一个或多个取代基,独立选择自卤素,(1-4C)烷基可选择地取代为一个或多个氟原子,(2-4C)炔基,(1-4C)氧烷基可选择地取代为一个或多个氟原子,氨基,二(1-4C)烷基氨基,-SO2-(1-4C)烷基,-CO-(1-4C)烷基,-CO-O-(1-4C)烷基,-NH-CO-(1-4C)烷基和(3-6C)环烷基,苯基取代为苯氧基,苄基,苄氧基,苯乙基或单环杂环烃,每个基团可选择地取代为(1-4C)烷基,单环杂环烃可选择地取代为卤素,(1-4C)烷基或取代为苯基的苯基,可选择地取代为(1-4C)烷基,和双环杂环烃可选择地取代为(1-4C)烷基;A从-CO-O-,-O-CO-,-NH-CO-,-CO-NH,-C=C-,-CCH3-O-和连接基-Y-(CH2)n-X-中选择,其中Y连接到R1并从键,-O-,-S-,-SO-,-SO2-,-CH2-O-,-CO-,-O-CO-,-CO-O-,-CO-NH-,-NH-CO-,-C=C-和-C≡C-中选择;n是1到10的整数;X连接到苯基/吡啶基团并从键,-O-,-S-,-SO-,-SO2-,-NH,-CO-,-C=C-和-C≡C-中选择;环结构B可选择地含有一个氮原子;R2是H,(1-4C)烷基可选择地取代为一个或多个氟原子,(1-4C)氧烷基可选择地取代为一个或多个氟原子,或卤素;R3是(1-4C)烷基-R5,其中烷基基团可取代为(CH2)2形成环丙基基团或一个或两个卤素原子,或R3是(3-6C)环烷基-R5或-CO-CH2-R5,其中R5是-OH,-PO3H2,-OPO3H2,-COOH,-COO(1-4C)烷基或四唑-5-基;R4是H或(1-4C)烷基;R6是一个或多个取代基,独立选择自H,(1-4C)烷基或氧代基;W是-O-,-S-,-SO-或-SO2-;或其药学上可接受的盐,溶剂或水合物;但是,公式(I)的衍生物不是2-(4-乙基苯基)-4-吗啉乙醇或4-[4-(2-羟乙基)-2-吗啉基]苯乙腈或其药学上可接受的盐,溶剂或水合物。本发明的化合物具有对S1P受体的亲和力,可用于治疗、缓解或预防S1P受体介导的疾病和症状。
  • A New Convenient Method for the Generation of Alkoxy Radicals from <i>N</i>-Alkoxydithiocarbamates
    作者:Sunggak Kim、Chae Jo Lim、Sang-Eun Song、Han-Young Kang
    DOI:10.1055/s-2001-13384
    日期:——
    N-Alkoxydithiocarbamates 2, which can be conveniently prepared from alkyl halides or alcohols using N-methylhydroxy-dithiocarbamate 1, are very useful precursors of alkoxy radicals.
    N-烷氧基二硫代氨基甲酸盐2,可以通过N-甲基羟基二硫代氨基甲酸盐1方便地从烷基卤化物或醇制备,是非常有用的烷氧基自由基前体。
  • Compounds having one or more aminosulfaonyloxy radicals useful as
    申请人:A. H. Robins Company, Incorporated
    公开号:US05194446A1
    公开(公告)日:1993-03-16
    Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula: (HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.z wherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.
    治疗慢性关节炎和骨质疏松症的方法利用已知和新颖的化合物,这些化合物可归入一般公式:(HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.z,其中A包括一系列值,包括但不限于芳基、较低烷基、环烷基和碳水化合物,包括蔗糖和果糖;p等于分子中未反应的羟基数,可以为零;z是--OS(O).sub.2 NR.sup.1 R.sup.2基团的数量,始终至少为一;R.sup.1和R.sup.2从氢、较低烷基、羧基等中选择;提供了一种制备这些化合物的新方法,其中适当的磺酸酯与含有保护羧基、氨基或羟基取代基的羟基取代的A基团在含有三级胺碱的无水溶剂中反应。还提供了用于治疗慢性关节炎和骨质疏松症的药物组合物。
查看更多